Acquired thrombopathia related to montelukast therapy

• References

• 1 Jones TR, Labelle M, Belley M. et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995; 73: 191-201.
• 2 Reiss TF, Chervinsky P, Dockhorn RJ. et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998; 158: 1213-20.
• 3 Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197-206.
• 4 Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. Br J Med 2002; 324: 1-7.
• 5 Mehta P, Mehta J, Lawson D. et al. Leukotrienes potentiate the effects of epinephrine and thrombin on human platelet aggregation. Thromb Res 1986; 41: 731-8.
• 6 Sarau HM, Ames RS, Chambers J. et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 1999; 56: 657-63.
• 7 Pace-Asciak CR, Klein J, Spielberg SP. Metabolism of leukotriene A4 into C4 by human platelets. Biochim Biophys Acta 1986; 877: 68-74.
• 8 Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 1990; 172: 1451.
• 9 Chabannes B, Moliere P, Mehri-Soussi F. et al. Platelets may inhibit leucotriene biosynthesis by human neutrophils at the integrin level. Br J Haematol 2003; 121: 341-8.